Robert F. Garry PhD is Professor of Microbiology and Immunology and Assistant Dean for Graduate Studies in Biomedical Sciences at Tulane University School of Medicine. Dr. Garry was involved in collaborative studies that lead to the determination that entry proteins of enveloped viruses form at least three distinct structural classes. This work has been the foundation for the development of novel antiviral peptide drugs. He is currently managing the Viral Hemorrhagic Fever Consortium (VHFC), a public -private partnership that is developing countermeasures against Lassa virus, Ebola virus and other severe pathogens. The VHFC developed point-of-contact, point-of-care and confirmatory diagnostics for Lassa fever to commercial standards. The VHFC leveraged these advances to develop high sensitivity and specificity immunoassays for Ebola virus and other filoviruses, including an Ebola Rapid Diagnostic Test (Ebola RDT) that can be used in austere settings. RDTs using VHFC critical reagents have been the only immunodiagnostics to obtain FDA Emergency Use Authorization and WHO Listing for use in the current West African Ebola outbreak.